The DOI matches its Crossref record.
Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group
Abstract
Background The absence of specific histological or serological markers, the gaps in understanding the aetiology and pathophysiology of rosacea, and the broad diversity in its clinical manifestations has made it difficult to reach international consensus on therapy guidelines. Objectives The main objective was to highlight the global diversity in current thinking about rosacea pathophysiology, classification and medical features, under particular consideration of the relevance of the findings to optimization of therapy. Methods The article presents findings, proposals and conclusions reached by the ROSacea International Expert group (ROSIE), comprising European and US rosacea experts. Results New findings on pathogenesis provide a rationale for the development of novel therapies. Thus, recent findings suggest a central role of the antimicrobial peptide cathelicidin and its activator kallikrein‐5 by eliciting an exacerbated response of the innate immune system. Cathelicidin/kallikrein‐5 also provide a rationale for the effect of tetracyclines and azelaic acid against rosacea. Clinically, the ROSIE group emphasized the need for a comprehensive therapy strategy – the triad of rosacea care – that integrates patient education including psychological and social aspects, skin care with dermo‐cosmetics as well as drug‐ and physical therapies. Classification of rosacea into stages or subgroups, with or without progression, remained controversial. However, the ROSIE group proposed that therapy decision making should be in accordance with a treatment algorithm based on the signs and symptoms of rosacea rather than on a prior classification. Conclusion The ROSIE group reviewed rosacea pathophysiology and medical features and the impact on patients and treatment options. The group suggested a rational, evidence‐based approach to treatment for the various symptoms of the condition. In daily practice this approach might be more easily handled than prior subtype classification, in particular since patients often may show clinical features of more than one subtype at the same time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Li, Y., Xiang, Q., Zhang, Q., Huang, Y., & Su, Z. (2012) · Peptides · doi:10.1016/j.peptides.2012.07.001 · Cited by 462
van Zuuren, E. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmcp1506630 · Cited by 299
Tüzün, Y., Wolf, R., Kutlubay, Z., Karakuş, Ö., & Engin, B. (2014) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2013.05.024 · Cited by 101
Wallen-Russell, C., Pearlman, N., Wallen-Russell, S., Cretoiu, D., Thompson, D. C., & Voinea, S. C. (2023) · Microorganisms · doi:10.3390/microorganisms11112784 · Cited by 14
Metadata
- Authors
- Elewski, B., Draelos, Z., Dréno, B., Jansen, T., Layton, A., & Picardo, M.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2011-01-04
- Volume
- 25
- Issue
- 2
- Pages
- 188-200
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W1656397836
- Cited by
- 207
- References
- 0
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. https://app.cochat.ai/papers/10.1111/j.1468-3083.2010.03751.x
- The paper
- Elewski, B., Draelos, Z., Dréno, B., Jansen, T., Layton, A., & Picardo, M. (2011). Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2010.03751.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.